A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects
Latest Information Update: 25 Apr 2014
At a glance
- Drugs PF 5230901 (Primary)
- Indications Cachexia
- Focus Adverse reactions
- Sponsors Pfizer
- 25 Apr 2014 New trial record